{
  "$schema": "folio-library-document/v1",
  "id": "10665-117378",
  "title": "[Pilot study of antiretroviral therapy in Djibouti]",
  "variant": "pdf",
  "pages": 12,
  "tocSource": "none",
  "tocMethod": null,
  "toc": [],
  "sections": [
    {
      "id": "page-001",
      "number": null,
      "title": "Page 1",
      "level": 1,
      "pageStart": 1,
      "pageEnd": 1,
      "labelStart": null,
      "labelEnd": null,
      "words": 519,
      "summary": {
        "text": "Opening page of a 2007 Eastern Mediterranean Health Journal article in French on a pilot antiretroviral therapy study in Djibouti, with an abstract describing a survey of 112 HIV-positive patients and their treatment efficacy. The Arabic abstract on this page was extracted as garbled text, and the footer also contains garbled characters.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "thérapie antirétrovirale",
          "heading": false
        },
        {
          "term": "djibouti",
          "heading": false
        },
        {
          "term": "antiretroviral therapy",
          "heading": false
        },
        {
          "term": "nrti",
          "heading": false
        },
        {
          "term": "ahmed",
          "heading": false
        },
        {
          "term": "santé",
          "heading": false
        },
        {
          "term": "patients",
          "heading": false
        }
      ],
      "extract": "1274 La Revue de Santé de la Méditerranée orientale, Vol. 13, N°6, 2007 Étude pilote de la thérapie antirétrovirale à Djibouti A.A. Ahmed' et S. Latoundji? Le er ie obus AU ball Aélroll 515 1 dl 35 PATES «at oLs je it Li ii AN cest cale Ce M ne 112 cé Le arcs Eu ci he ge Ja qe sil ec all) de fall doté QUE on dif 8 Lie 5 Eu LL, ah star Dr ep à bi ce 190 DS y cts 36 ALL Gi ue jouit Cho Os (L/iseus 400 + NRTI 2 gif tte",
      "extractCut": true,
      "blocks": [
        "library/10665-117378/blocks/prose-page-001"
      ]
    },
    {
      "id": "page-002",
      "number": null,
      "title": "Page 2",
      "level": 1,
      "pageStart": 2,
      "pageEnd": 2,
      "labelStart": null,
      "labelEnd": null,
      "words": 577,
      "summary": {
        "text": "Introduces the Djibouti antiretroviral therapy study, giving the country's HIV prevalence, treatment eligibility criteria and first- and second-line regimens. It sets out the study objectives and begins describing methods, including how virological efficacy was assessed; the footer is garbled text.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "lymphocytes totaux",
          "heading": false
        },
        {
          "term": "transcriptase inverse",
          "heading": false
        },
        {
          "term": "cette enquête",
          "heading": false
        },
        {
          "term": "des données",
          "heading": false
        },
        {
          "term": "charge virale",
          "heading": false
        },
        {
          "term": "agit une",
          "heading": false
        },
        {
          "term": "inti",
          "heading": false
        },
        {
          "term": "nucléosidiques",
          "heading": false
        }
      ],
      "extract": "Eastern Mediterranean Health Journal, Vol. 13, No. 6, 2007 Introduction La République de Djibouti, d’une superficie de 23 000 km?, compte 690 000 habitants. La séroprévalence du VIH est de 2,9 % et l’on estime à 9100 le nombre de personnes vivant avec le VIH dans le pays [7]. La mise à disposition du traitement antirétroviral a démarré en mars 2004. Est éligible au trai- tement antirétroviral tout patient",
      "extractCut": true,
      "blocks": [
        "library/10665-117378/blocks/prose-page-002"
      ]
    },
    {
      "id": "page-003",
      "number": null,
      "title": "Page 3",
      "level": 1,
      "pageStart": 3,
      "pageEnd": 3,
      "labelStart": null,
      "labelEnd": null,
      "words": 606,
      "summary": {
        "text": "Defines the criteria for virological and immunological success or failure and for blood abnormalities, and describes the laboratory techniques used for CD4 counts, viral load and blood counts. It begins the results with patients' sociodemographic profile; the footer contains garbled text.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "une anémie",
          "heading": false
        },
        {
          "term": "virale est",
          "heading": false
        },
        {
          "term": "réalisée aide",
          "heading": false
        },
        {
          "term": "charge virale",
          "heading": false
        },
        {
          "term": "comparaison des",
          "heading": false
        },
        {
          "term": "correspond une",
          "heading": false
        },
        {
          "term": "les variables",
          "heading": false
        },
        {
          "term": "des patients",
          "heading": false
        }
      ],
      "extract": "1276 mois de traitement, on considère qu’il y a un échec virologique si la charge virale est supérieure ou égale à 400 copies/mL et un succès virologique si la charge virale est inférieure à 400 copies/mL. On considère qu’il y a un succès immunologique si on a une augmentation de plus de 20 % du taux de CDA initial et un échec si on a moins de 20 %. Un taux d’hémoglobine < 12 g/dL correspond à une anémie, des",
      "extractCut": true,
      "blocks": [
        "library/10665-117378/blocks/prose-page-003"
      ]
    },
    {
      "id": "page-004",
      "number": null,
      "title": "Page 4",
      "level": 1,
      "pageStart": 4,
      "pageEnd": 4,
      "labelStart": null,
      "labelEnd": null,
      "words": 538,
      "summary": {
        "text": "Reports where patients in the Djibouti study were followed up and their main opportunistic infections at treatment start, with a table of sociodemographic characteristics. It gives the share of patients achieving virological success and notes that efficacy did not differ by regimen.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "inti innti",
          "heading": false
        },
        {
          "term": "les caractéristiques",
          "heading": false
        },
        {
          "term": "patients sont",
          "heading": false
        },
        {
          "term": "des patients",
          "heading": false
        },
        {
          "term": "stade",
          "heading": false
        },
        {
          "term": "présen",
          "heading": false
        },
        {
          "term": "virologique",
          "heading": false
        },
        {
          "term": "immuno-virologique",
          "heading": false
        }
      ],
      "extract": "Eastern Mediterranean Health Journal, Vol. 13, No. 6, 2007 1277 de Balbala (arrondissements 4 & 5) suivent leur traitement à l’hôpital général Peltier. Les patients sont suivis à l'hôpital général Peltier (36 %), le centre Yonis Toussaint (27 %), le centre hospitalier des armées françaises Bouffard (21 %), le centre Paul Faure (8 %), les deux centres de santé de l’Organisme de Protection Sociale (7 %) et le centre",
      "extractCut": true,
      "blocks": [
        "library/10665-117378/blocks/prose-page-004"
      ]
    },
    {
      "id": "page-005",
      "number": null,
      "title": "Page 5",
      "level": 1,
      "pageStart": 5,
      "pageEnd": 5,
      "labelStart": null,
      "labelEnd": null,
      "words": 396,
      "summary": {
        "text": "Presents a table of the study population's clinical, biological and treatment characteristics and reports significant clinical improvement, such as gains in Karnofsky index and body mass index and fewer opportunistic infections. It ends with a table listing the antiretroviral combinations prescribed.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "lopinavir ritonavir",
          "heading": false
        },
        {
          "term": "affections opportunistes",
          "heading": false
        },
        {
          "term": "didanosine",
          "heading": false
        },
        {
          "term": "nbre",
          "heading": false
        },
        {
          "term": "imc",
          "heading": false
        },
        {
          "term": "zidovudine",
          "heading": false
        },
        {
          "term": "ddi",
          "heading": false
        },
        {
          "term": "azt",
          "heading": false
        }
      ],
      "extract": "1278 La Revue de Santé de la Méditerranée orientale, Vol. 13, N°6, 2007 Tableau 2 Description clinique, biologique et thérapeutique de la population d’étude Caractéristiques Initiation IK(%) Médiane (ElQ) 80 (70-90) IMC (kg/m?) Médiane (ElQ) Affections opportunistes [Nbre (%)] Stade clinique à l'inclusion [Nbre (%)] 18,6 (15,9-21,5) 101 (90,2 %) Stade À 8 (7) Stade B 29 (26) Stade C 75 (67) Taux de CD4 (Imm*)",
      "extractCut": true,
      "blocks": [
        "library/10665-117378/blocks/prose-page-005"
      ]
    },
    {
      "id": "page-006",
      "number": null,
      "title": "Page 6",
      "level": 1,
      "pageStart": 6,
      "pageEnd": 6,
      "labelStart": null,
      "labelEnd": null,
      "words": 573,
      "summary": {
        "text": "Gives a table of immunological and virological efficacy and reports a strong correlation between total lymphocytes and CD4 counts, testing different lymphocyte thresholds for starting treatment. It identifies predictors of failure and opens the discussion on low treatment coverage in Djibouti.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "avancé",
          "heading": false
        },
        {
          "term": "virologique",
          "heading": false
        },
        {
          "term": "stade",
          "heading": false
        }
      ],
      "extract": "Eastern Mediterranean Health Journal, Vol. 13, No. 6, 2007 1279 Tableau 4 Efficacité immunologique et virologique Nbre (%) Niveau virologique (copiesimL) CV = 400 29 (26) CV < 400 83 (74) Niveau immunologique : coefficient d’ascension du taux de CD4 initial > 20 % 80 (71) <20% 32 (29 CV: charge virale. Le coefficient de Spearman (r = 0,51 ; p < 0,0001) montre une forte corrélation entre les deux variables. Les",
      "extractCut": true,
      "blocks": [
        "library/10665-117378/blocks/prose-page-006"
      ]
    },
    {
      "id": "page-007",
      "number": null,
      "title": "Page 7",
      "level": 1,
      "pageStart": 7,
      "pageEnd": 7,
      "labelStart": null,
      "labelEnd": null,
      "words": 302,
      "summary": {
        "text": "Presents a table comparing clinical, immunological, haematological and biochemical parameters at treatment start and at the time of the survey. The discussion begins comparing the sociodemographic profile with African studies.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "elq",
          "heading": false
        },
        {
          "term": "transaminase glutamique",
          "heading": false
        },
        {
          "term": "médiane",
          "heading": false
        },
        {
          "term": "affections opportunistes",
          "heading": false
        },
        {
          "term": "paramètres",
          "heading": false
        },
        {
          "term": "imc",
          "heading": false
        },
        {
          "term": "indice",
          "heading": false
        },
        {
          "term": "des",
          "heading": false
        }
      ],
      "extract": "1280 La Revue de Santé de la Méditerranée orientale, Vol. 13, N°6, 2007 Tableau 5 Comparaison des paramètres cliniques et biologiques de la population d’étude en début du traitement antirétroviral et au moment de l’enquête selon des séries appariées Paramètres Initiation Enquête (n=112) (n=112) Plan clinique IMC (kg/m?) Médiane (ElQ) 18,6 (15,9-21,5) 20,7(18,3-22,6) 0,0001° IK (%) Médiane (ElQ) 0,8 (0,7-0,9)",
      "extractCut": true,
      "blocks": [
        "library/10665-117378/blocks/prose-page-007"
      ]
    },
    {
      "id": "page-008",
      "number": null,
      "title": "Page 8",
      "level": 1,
      "pageStart": 8,
      "pageEnd": 8,
      "labelStart": null,
      "labelEnd": null,
      "words": 345,
      "summary": {
        "text": "Shows a regression plot of the correlation between total lymphocytes and CD4 cells at treatment start, with the figure partly extracted as garbled characters. The discussion compares opportunistic infections, HIV-1 predominance and protease inhibitor use with other African countries and explains the clinical improvement seen.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "affections opportunistes",
          "heading": false
        },
        {
          "term": "lymphocytes totaux",
          "heading": false
        },
        {
          "term": "des affections",
          "heading": false
        },
        {
          "term": "les lymphocytes",
          "heading": false
        },
        {
          "term": "explique par",
          "heading": false
        },
        {
          "term": "bénin",
          "heading": false
        },
        {
          "term": "l'initiation",
          "heading": false
        },
        {
          "term": "protéase",
          "heading": false
        }
      ],
      "extract": "Eastern Mediterranean Health Journal, Vol. 13, No. 6, 2007 1281 600 - ° 400 - o o co G 200- 02 °6fo : : | ° Le) go \"8 800 EUX 5 | 8 og8o8l6e oê o o 07 o 2007 nomme Damme TT …— T | | | 0,0 1,0 2,0 30 3 Lymphocytes totaux o CD4 “ Valeurs ajustées Figure 1 Représentation graphique selon un modèle de régression linéaire de la corrélation entre les lymphocytes totaux (LT) et les lymphocytes T CD4 à l'initiation du",
      "extractCut": true,
      "blocks": [
        "library/10665-117378/blocks/prose-page-008"
      ]
    },
    {
      "id": "page-009",
      "number": null,
      "title": "Page 9",
      "level": 1,
      "pageStart": 9,
      "pageEnd": 9,
      "labelStart": null,
      "labelEnd": null,
      "words": 228,
      "summary": {
        "text": "A table from the multivariate logistic regression identifying factors that predict treatment success, including treatment centre, initial Karnofsky index and clinical stage.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "analyse multivariée",
          "heading": false
        },
        {
          "term": "inti",
          "heading": false
        },
        {
          "term": "stade",
          "heading": false
        },
        {
          "term": "cpf",
          "heading": false
        },
        {
          "term": "cyt",
          "heading": false
        }
      ],
      "extract": "1282 La Revue de Santé de la Méditerranée orientale, Vol. 13, N°6, 2007 Tableau 6 Analyse multivariée selon un modèle de régression logistique permettant d'identifier les facteurs prédictifs du succès thérapeutique Variables incluses Analyse univariée Analyse multivariée dans le modèle OR (IC 95 %) OR (IC 95 %) Centre CHA 1,00 CPF 0,4 (0,1-1,8) 0,4 (0,06-2,4) CYT 6,4 (1,5-27) 6,1 (1,2-30,3) HGP 0,9 (0,4-2,7) 1,3",
      "extractCut": true,
      "blocks": [
        "library/10665-117378/blocks/prose-page-009"
      ]
    },
    {
      "id": "page-010",
      "number": null,
      "title": "Page 10",
      "level": 1,
      "pageStart": 10,
      "pageEnd": 10,
      "labelStart": null,
      "labelEnd": null,
      "words": 577,
      "summary": {
        "text": "Continues the discussion, comparing treatment efficacy with other countries and noting immunological-virological discordance. It discusses the limits of total lymphocyte counts as a CD4 substitute, attributes viral rebound mainly to poor adherence, and notes possible information and classification biases.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "traitement antirétroviral",
          "heading": false
        },
        {
          "term": "sous traitement",
          "heading": false
        },
        {
          "term": "les lymphocytes",
          "heading": false
        },
        {
          "term": "lymphocytes totaux",
          "heading": false
        },
        {
          "term": "est pas",
          "heading": false
        },
        {
          "term": "retrouve une",
          "heading": false
        },
        {
          "term": "les patients",
          "heading": false
        },
        {
          "term": "des patients",
          "heading": false
        }
      ],
      "extract": "Eastern Mediterranean Health Journal, Vol. 13, No. 6, 2007 et 124 au Sénégal [3]. L'efficacité théra- peutique rejoint celle observée au Bénin [4], au Sénégal [3], en Europe [72] et aux États-Unis d'Amérique [73,14]. Cepen- dant, on retrouve une discordance immuno- virologique chez nos patients [72]. Le dosage des lymphocytes totaux n’est pas spécifique aux LT CD4 puisqu'ils re- groupent, en plus des LT CDA4, les",
      "extractCut": true,
      "blocks": [
        "library/10665-117378/blocks/prose-page-010"
      ]
    },
    {
      "id": "page-011",
      "number": null,
      "title": "Page 11",
      "level": 1,
      "pageStart": 11,
      "pageEnd": 11,
      "labelStart": null,
      "labelEnd": null,
      "words": 505,
      "summary": {
        "text": "Concludes that antiretroviral therapy is feasible and effective in Djibouti but that central structures and care of opportunistic infections should be strengthened before scale-up. Acknowledgements and the start of the reference list follow.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "béninoise d'accès",
          "heading": false
        },
        {
          "term": "l'initiative béninoise",
          "heading": false
        },
        {
          "term": "infections opportunistes",
          "heading": false
        },
        {
          "term": "thèse",
          "heading": false
        },
        {
          "term": "traitement antirétroviral",
          "heading": false
        },
        {
          "term": "cotonou",
          "heading": false
        },
        {
          "term": "d'accès aux",
          "heading": false
        },
        {
          "term": "sous traitement",
          "heading": false
        }
      ],
      "extract": "1284 Conclusion Cette étude, portant sur la première cohorte djiboutienne mise sous traitement antirétro- viral, montre que le traitement antirétroviral est faisable et efficace à Djibouti. Avant son extension à l’ensemble du territoire, il est nécessaire de renforcer les structures centrales et la prise en charge des infections opportunistes. La Revue de Santé de la Méditerranée orientale, Vol. 13, N°6, 2007",
      "extractCut": true,
      "blocks": [
        "library/10665-117378/blocks/prose-page-011"
      ]
    },
    {
      "id": "page-012",
      "number": null,
      "title": "Page 12",
      "level": 1,
      "pageStart": 12,
      "pageEnd": 12,
      "labelStart": null,
      "labelEnd": null,
      "words": 235,
      "summary": {
        "text": "The end of the reference list for the Djibouti antiretroviral therapy article, citing mainly AIDS and JAMA studies on CD4 counts, total lymphocyte counts, drug resistance and adverse effects.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "antiretroviral therapy",
          "heading": false
        },
        {
          "term": "active antiretroviral",
          "heading": false
        },
        {
          "term": "ids",
          "heading": false
        },
        {
          "term": "cotonou",
          "heading": false
        },
        {
          "term": "medical association",
          "heading": false
        },
        {
          "term": "count",
          "heading": false
        },
        {
          "term": "journal",
          "heading": false
        }
      ],
      "extract": "Eastern Mediterranean Health Journal, Vol. 13, No. 6, 2007 15. 16. 17. 18. 19. Chêne G et al. Change in CD4+ cell count and the risk of opportunistic infection or death after highly active antiretroviral treatment. A/IDS, 1998, 12(17):2313-20. Badri M, Wood R. Usefulness of total lym- phocyte count in moritoring highly active antiretroviral therapy in resource-limited settings. A/IDS, 2003, 17:541-5. Jacobson MA et",
      "extractCut": true,
      "blocks": [
        "library/10665-117378/blocks/prose-page-012"
      ]
    }
  ],
  "checks": {},
  "withheld": false,
  "keywords": [
    {
      "term": "des affections",
      "heading": false
    },
    {
      "term": "les lymphocytes",
      "heading": false
    },
    {
      "term": "les patients",
      "heading": false
    },
    {
      "term": "charge des",
      "heading": false
    },
    {
      "term": "traitement antirétroviral",
      "heading": false
    },
    {
      "term": "pour les",
      "heading": false
    },
    {
      "term": "que les",
      "heading": false
    },
    {
      "term": "dans les",
      "heading": false
    },
    {
      "term": "les stades",
      "heading": false
    },
    {
      "term": "affections opportunistes",
      "heading": false
    },
    {
      "term": "les deux",
      "heading": false
    },
    {
      "term": "entre les",
      "heading": false
    }
  ],
  "coverage": [
    {
      "kind": "contents",
      "state": "not-extracted",
      "note": "split one section per page; no contents was trusted"
    },
    {
      "kind": "sections",
      "state": "partial",
      "count": 12,
      "note": "one per page, not by heading"
    },
    {
      "kind": "figures",
      "state": "none"
    },
    {
      "kind": "tables",
      "state": "not-extracted"
    },
    {
      "kind": "references",
      "state": "not-extracted",
      "note": "a references section is in the text (p11); its entries are not extracted"
    },
    {
      "kind": "glossary",
      "state": "none",
      "note": "no such heading in the text"
    },
    {
      "kind": "footnotes",
      "state": "none"
    },
    {
      "kind": "summaries",
      "state": "found",
      "count": 12,
      "note": "12 of 12 sections"
    }
  ],
  "links": {
    "repo": "litlfred/who-iris",
    "branch": "main",
    "dir": "library/10665-117378"
  }
}
